Merck KGaA’s (MRK) “Buy” Rating Reaffirmed at DZ Bank
Merck KGaA (FRA:MRK)‘s stock had its “buy” rating reaffirmed by equities researchers at DZ Bank in a report released on Wednesday, Borsen Zeitung reports.
Several other equities research analysts have also recently weighed in on the company. Warburg Research set a €103.00 ($119.77) target price on Merck KGaA and gave the stock a “neutral” rating in a research note on Tuesday, July 30th. Barclays set a €82.00 ($95.35) target price on shares of Merck KGaA and gave the stock a “sell” rating in a research report on Wednesday. Morgan Stanley set a €96.00 ($111.63) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Tuesday, June 18th. Nord/LB set a €94.00 ($109.30) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a report on Friday, August 9th. Finally, Credit Suisse Group set a €110.00 ($127.91) price target on shares of Merck KGaA and gave the stock a “buy” rating in a report on Thursday, August 8th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of €100.67 ($117.05).
FRA MRK traded down €1.60 ($1.86) on Wednesday, hitting €93.52 ($108.74). 278,984 shares of the company’s stock were exchanged. The business has a 50-day moving average price of €93.68. Merck KGaA has a 52 week low of €76.60 ($89.07) and a 52 week high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Article: Futures Contract
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.